Understanding Access and Costs for Prostate Cancer Care
Chad Tang, MD, along with Benjamin Smith, MD, and Grace Smith, MD, PhD, MPH, at the University of Texas MD Anderson Cancer Center are conducting an analysis to understand the barriers to access and costs associated with four treatment options for patients with prostate cancer—surgery, external beam radiation therapy, brachytherapy and active surveillance. Prostate cancer is the most common cancer among men in the U.S., but many patients are not presented with the full array of radiation treatment options due to complex factors, including referral, reimbursement, training and the limited number of radiation oncologists, especially those practicing brachytherapy. Dr. Tang’s study will be the first national-level analysis of the costs, financial toxicity and utilization of these four treatment options, and the results could be used to help increase access to radiation therapy for patients with prostate cancer across the U.S.
In the study, Dr. Tang’s team is:
- Assessing national trends in the number and location of providers who routinely offer each of the four prostate cancer treatment options. From this data, they will create a map of the U.S. that shows the relative utilization of each treatment with a focus on where prostate cancer patients’ options are limited.
- Comparing patient and payer costs for the four treatment options, including those directly associated with treatment, the total costs over a six-month window starting with diagnosis, and the costs incurred after the treatment is completed.
- Conducting a prospective survey of patients being treated with surgery and brachytherapy at their institution to evaluate financial toxicity.
Data from the MarketScan and Medicare databases is being used, which will provide a balanced view across private and public health insurance in both young and old prostate cancer patients nationwide. The results from Dr. Tang’s ROI-funded analysis will support the development of a larger prospective observational study on the financial burden of the different treatment options available to prostate cancer patients.